Hyderabad based Aurobindo Pharma Ltd. has garnered the approval of United States Food and Drug Administration (USFDA) to manufacture and market 2 drugs. One being, the generic version of Boehringer Ingelheim Pharmaceuticals’ manufactured Flomax (Tamsulosin hydrochloride) capsule used for treatment of symptoms of enlarged prostate in men. The other being generic version of Pharmacia & Upjohn’s Cleocin Pediatric (Clindamycin Palmitate Hydrochloride) used for treatment of serious infections caused by susceptible anaerobic bacteria in minors. The approval will position Aurobindo Pharma on a higher rung in the Indian pharmaceutical industry.
The products are expected to be launched soon and would thereby add to Aurobindo Pharma’s Abbreviated New Drug Application (ANDA) approvals from USFDA to 190. The Indian pharmaceutical market is being recognized majorly for its generic drugs that is bringing high priced drugs within affordability.